News Sentiment

ILMN sentiment intelligence

Illumina Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 186.65 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend active

-1.9% over one week, +15.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Illumina stock trades steady as investors weigh Q1 2026 revenue decline and cost-cutting plan

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction -1.9% Price digesting
Trend fit Trend active 15.3% over four weeks
Fair value 52.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 34
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Ad-hoc-news.de 8
Market source 7
Stock Titan 7
simplywall.st 5
TradingView 5
PR Newswire 4
MarketWatch 3
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 14
Regulatory and legal 3
Analyst action 3
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
MarketWatch Direct company coverage

Illumina Inc. stock outperforms competitors on strong trading day

Illumina Inc. (ILMN) stock increased by 3.17% to $193.76, outperforming the broader market during a positive trading session. This rise ended a two-day losing streak for the company's shares. The S&P 500 Index and Dow Jones Industrial Average also saw gains, rising 0.81% and 0.27

Tone
Positive 70/100
Event
Market update
Published
09 Jul 2026 17:22
Source
MarketWatch
MarketWatch Direct company coverage

Illumina Inc. stock outperforms competitors despite losses on the day

Illumina Inc. (ILMN) shares fell 2.06% to $187.81, marking its second consecutive day of losses. Despite this decline, the stock still outperformed the broader market, as the S&P 500 Index and Dow Jones Industrial Average also experienced losses on the day.

Tone
Negative 38/100
Event
Market update
Published
08 Jul 2026 17:21
Source
MarketWatch
Market source Direct company coverage

Illumina, Inc. (ILMN) Hit a 52 Week High, Can the Run Continue?

Illumina (ILMN) shares recently hit a 52-week high, surging 19.8% in the past month and 46.2% year-to-date, outperforming the Zacks Medical sector. The company has consistently beaten earnings estimates, with expected EPS growth. While its valuation metrics are higher than indust

Tone
Positive 76/100
Event
Earnings
Published
08 Jul 2026 13:39
Source
Market source
MarketWatch Direct company coverage

Illumina Inc. stock underperforms Tuesday when compared to competitors

Shares of Illumina Inc. (ILMN) fell 1.32% on Tuesday, closing at $191.76, amidst a general market downturn where the S&P 500 Index and Dow Jones Industrial Average also declined. This dip ended a three-day winning streak for Illumina's stock. The article highlights Illumina's und

Tone
Negative 38/100
Event
Market update
Published
07 Jul 2026 17:22
Source
MarketWatch
Simply Wall Street Direct company coverage

Is Illumina (ILMN) Quietly Recasting Its Clinical Genomics Strategy With Eli Lilly’s R&D Chief on Board?

Illumina recently appointed Daniel M. Skovronsky, Eli Lilly’s Chief Scientific and Product Officer, to its board, potentially influencing its clinical genomics and next-generation sequencing strategy. This move aligns with Illumina's focus on clinical applications like minimal re

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 03:39
Source
Simply Wall Street
Stock Traders Daily Direct company coverage

(ILMN) Risk Channels and Responsive Allocation

This article analyzes Illumina Inc. (ILMN), indicating a strong overweight bias across all time horizons based on AI models. It highlights the absence of resistance levels above the current price, suggesting significant upside potential. Three distinct trading strategies are pres

Tone
Positive 73/100
Event
Market update
Published
05 Jul 2026 03:11
Source
Stock Traders Daily
TradingView Direct company coverage

Should You Continue to Hold ILMN Stock in Your Portfolio?

Illumina Inc. (ILMN) is poised for growth due to its focus on core sequencing, multiomics expansion, and strong NovaSeq X placements, despite challenges in the China market and macroeconomic pressures. The company surpassed Q1 2026 estimates, raised full-year guidance, and sees c

Tone
Positive 69/100
Event
Guidance
Published
03 Jul 2026 12:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Illumina, Inc. – NASDAQ:ILMN

This article provides access to the "Price to sales forward" metric for Illumina, Inc. (NASDAQ: ILMN) on the TradingView platform. It is a financial data point for the health technology company. The content appears to be a truncated view of a financial data page rather than a det

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 02:39
Source
TradingView
Investing.com Canada Direct company coverage

Form 4 Illumina Inc For: 2 July By Investing.com

This article reports on a Form 4 filing for Illumina Inc. dated July 2nd. It notes a 2.60% increase in ILMN stock and provides an overview of various financial market data including indices, commodities, bonds, and trending stocks. The content is presented by Investing.com, a fin

Tone
Positive 60/100
Event
Market update
Published
02 Jul 2026 22:14
Source
Investing.com Canada
Stock Titan Direct company coverage

[Form 4] ILLUMINA, INC. Insider Trading Activity

ILLUMINA, INC. director Scott B. Ullem reported an acquisition of 167 shares of common stock on June 30, 2026, as compensation for his second-quarter board and committee retainer fees. The shares, valued at $149.1868 each, were granted based on the volume-weighted average closing

Tone
Neutral 50/100
Event
Deals and strategy
Published
02 Jul 2026 22:14
Source
Stock Titan
Stock Titan Direct company coverage

Illumina (ILMN) director takes 2026 board fees entirely in stock

Illumina director Keith A. Meister has opted to receive 100% of his 2026 board and committee cash retainer fees in company stock. For the second quarter of 2026, this resulted in a grant of 142 shares at a reference price of $149.1868 per share, increasing his direct holdings to

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 22:14
Source
Stock Titan
Finviz Direct company coverage

ILMN - Illumina Inc Volatility & Greeks

This article provides a detailed snapshot of Illumina Inc. (ILMN) financial and stock performance data as of July 2, 2026. It includes key metrics such as market capitalization, income, sales, various P/E ratios, EPS growth rates, insider and institutional ownership, profitabilit

Tone
Positive 63/100
Event
Earnings
Published
02 Jul 2026 18:39
Source
Finviz
Insider Monkey Direct company coverage

Illumina (ILMN) Gets Bernstein’s Market Perform Rating Amid NovaSeq X Recovery

Bernstein SocGen analyst Eve Burstein has resumed coverage of Illumina (NASDAQ: ILMN) with a Market Perform rating and a $185 price target, citing the company's recovery from a difficult period. Illumina faced challenges in early 2025 due to China restricting imports of its seque

Tone
Positive 60/100
Event
Analyst action
Published
01 Jul 2026 17:30
Source
Insider Monkey
Investing.com Direct company coverage

Piper Sandler raises Illumina stock price target on clinical strength

Piper Sandler increased its price target for Illumina (NASDAQ:ILMN) to $200 from $170, maintaining an Overweight rating, based on the company's strong clinical business momentum and dominance in the genomics market. The firm highlighted Illumina's NovaSeq X system, which accounts

Tone
Positive 70/100
Event
Analyst action
Published
01 Jul 2026 13:29
Source
Investing.com
MedTech Dive Direct company coverage

Roche takes on Illumina with new NGS system

Roche is entering the next-generation sequencing market with its new Axelios 1 system, directly challenging Illumina's long-standing dominance. The Axelios 1 platform utilizes a novel "sequencing by expansion" (SBX) technology, which Roche claims offers improved accuracy, scalabi

Tone
Negative 34/100
Event
Market update
Published
30 Jun 2026 20:40
Source
MedTech Dive
TradingView Direct company coverage

Price to earnings forward of Illumina, Inc. – TURQUOISE:ILMNN

This article displays the "Price to earnings forward" value for Illumina, Inc. (ILMNN) on the Turquoise market. It indicates that the market is currently closed with no trades. The data is provided by ICE Data Services and FactSet Research Systems Inc.

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 10:41
Source
TradingView